Tags

Type your tag names separated by a space and hit enter

Abdominal obesity phenotypes and risk of cardiovascular disease in a decade of follow-up: the Tehran Lipid and Glucose Study.
Atherosclerosis. 2015 Feb; 238(2):256-63.A

Abstract

OBJECTIVE

Obesity is a heterogeneous condition and risk of related health outcomes in different obesity phenotypes is a controversial subject. In this study, we aimed to evaluate the risk of cardiovascular disease (CVD) in different abdominal obesity phenotypes during a decade-long follow-up.

METHODS

In this large population-based cohort, 7122 participants (42.7% men), aged ≥30 years, from the Tehran Lipid and Glucose Study (TLGS) were enrolled. Abdominal obesity was defined using national waist circumference cut-off points of ≥89 cm for men and ≥91 cm for women. Metabolic health was defined as ≤1 components of metabolic syndrome (excluding waist circumference), using the Joint Interim Statement (JIS) definition.

RESULTS

At baseline, 3745 individuals (52.7%) were abdominal obese and 23.5% (n = 881) of these were categorized as "metabolically healthy abdominal obese" (MHAO). A total of 638 CVD events occurred during a median follow-up of 10 years (1999-2011). "Metabolically healthy non-abdominal obese" was considered as the reference group. After adjustment for various variables, MHAO individuals were at increased risk for CVD events compared with the reference group (HR: 1.64, CI: 1.09-2.47). Both the metabolically unhealthy phenotypes (with and without abdominal obesity) were also at increased risk. We also observed the same pattern using insulin resistance data for categorizing abdominal obesity phenotypes.

CONCLUSION

Abdominal obesity and presence of metabolic derangements are both important risk factors for future CVD. MHAO may not be a benign condition regarding future CVD events, which highlights the importance of prevention and treatment of abdominal obesity, even in the absence of metabolic derangements.

Authors+Show Affiliations

Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Science, Tehran, Iran. Electronic address: sorena.keihani@gmail.com.Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Science, Tehran, Iran. Electronic address: fhospanah@endocrine.ac.ir.Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Science, Tehran, Iran. Electronic address: m.barzin7@gmail.com.Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Science, Tehran, Iran. Electronic address: sara.serahati@gmail.com.Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Science, Tehran, Iran. Electronic address: sorayadoust@yahoo.com.Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Science, Tehran, Iran. Electronic address: azizi@endocrine.ac.ir.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

25540856

Citation

Keihani, Sorena, et al. "Abdominal Obesity Phenotypes and Risk of Cardiovascular Disease in a Decade of Follow-up: the Tehran Lipid and Glucose Study." Atherosclerosis, vol. 238, no. 2, 2015, pp. 256-63.
Keihani S, Hosseinpanah F, Barzin M, et al. Abdominal obesity phenotypes and risk of cardiovascular disease in a decade of follow-up: the Tehran Lipid and Glucose Study. Atherosclerosis. 2015;238(2):256-63.
Keihani, S., Hosseinpanah, F., Barzin, M., Serahati, S., Doustmohamadian, S., & Azizi, F. (2015). Abdominal obesity phenotypes and risk of cardiovascular disease in a decade of follow-up: the Tehran Lipid and Glucose Study. Atherosclerosis, 238(2), 256-63. https://doi.org/10.1016/j.atherosclerosis.2014.12.008
Keihani S, et al. Abdominal Obesity Phenotypes and Risk of Cardiovascular Disease in a Decade of Follow-up: the Tehran Lipid and Glucose Study. Atherosclerosis. 2015;238(2):256-63. PubMed PMID: 25540856.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Abdominal obesity phenotypes and risk of cardiovascular disease in a decade of follow-up: the Tehran Lipid and Glucose Study. AU - Keihani,Sorena, AU - Hosseinpanah,Farhad, AU - Barzin,Maryam, AU - Serahati,Sara, AU - Doustmohamadian,Soraya, AU - Azizi,Fereidoun, Y1 - 2014/12/09/ PY - 2014/08/29/received PY - 2014/11/30/revised PY - 2014/12/04/accepted PY - 2014/12/26/entrez PY - 2014/12/30/pubmed PY - 2015/9/22/medline KW - Abdominal obesity KW - Cardiovascular disease KW - Metabolic syndrome KW - Metabolically healthy obesity SP - 256 EP - 63 JF - Atherosclerosis JO - Atherosclerosis VL - 238 IS - 2 N2 - OBJECTIVE: Obesity is a heterogeneous condition and risk of related health outcomes in different obesity phenotypes is a controversial subject. In this study, we aimed to evaluate the risk of cardiovascular disease (CVD) in different abdominal obesity phenotypes during a decade-long follow-up. METHODS: In this large population-based cohort, 7122 participants (42.7% men), aged ≥30 years, from the Tehran Lipid and Glucose Study (TLGS) were enrolled. Abdominal obesity was defined using national waist circumference cut-off points of ≥89 cm for men and ≥91 cm for women. Metabolic health was defined as ≤1 components of metabolic syndrome (excluding waist circumference), using the Joint Interim Statement (JIS) definition. RESULTS: At baseline, 3745 individuals (52.7%) were abdominal obese and 23.5% (n = 881) of these were categorized as "metabolically healthy abdominal obese" (MHAO). A total of 638 CVD events occurred during a median follow-up of 10 years (1999-2011). "Metabolically healthy non-abdominal obese" was considered as the reference group. After adjustment for various variables, MHAO individuals were at increased risk for CVD events compared with the reference group (HR: 1.64, CI: 1.09-2.47). Both the metabolically unhealthy phenotypes (with and without abdominal obesity) were also at increased risk. We also observed the same pattern using insulin resistance data for categorizing abdominal obesity phenotypes. CONCLUSION: Abdominal obesity and presence of metabolic derangements are both important risk factors for future CVD. MHAO may not be a benign condition regarding future CVD events, which highlights the importance of prevention and treatment of abdominal obesity, even in the absence of metabolic derangements. SN - 1879-1484 UR - https://www.unboundmedicine.com/medline/citation/25540856/Abdominal_obesity_phenotypes_and_risk_of_cardiovascular_disease_in_a_decade_of_follow_up:_the_Tehran_Lipid_and_Glucose_Study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0021-9150(14)01615-3 DB - PRIME DP - Unbound Medicine ER -